- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Supernus Pharmaceuticals Inc
+ Add to WatchlistSUPN:US
6.3000 USD 0.0400 0.64%As of 17:20:00 ET on 05/21/2013.
Snapshot for Supernus Pharmaceuticals Inc (SUPN)
| Open: | 6.2200 | Day's Range: | 6.1600 - 6.4500 | Volume: | 728,335 |
|---|---|---|---|---|---|
| Previous Close: | 6.2600 | 52wk Range: | 4.3000 - 16.6800 | 1-Yr Rtn: | +13.72% |
Key Statistics for SUPN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.2700 |
| Est. EPS (USD) (12/2013) | -2.4630 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 195.21 |
| Shares Outstanding (M) | 30.99 |
| 30 Day Average Volume | 637,343 |
| Price/Book (mrq) | 3.3510 |
| Price/Sale (ttm) | 114.9054 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SUPN
Company Profile & Key Executives for SUPN
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus has developed a portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson's disease, ADHD, depression and anxiety.
| Jack A KhattarPresident/CEO/Secy/Founder | Stefan K F SchwabeExec VP:R&D/Chief Medical Ofcr |
| Padmanabh P Bhatt PhdSenior VP:Intellectual Property | Victor VaughnSenior VP:Sales |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
SUPN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page